title: Use of an active center-directed plasmin inhibitor elucidates the multiplicity of plasmin actions.
abstract: In our studies, designed to synthesize an active center-directed plasmin (PL) inhibitor, N-(4-aminomethylbenzoyl)-4-(3-picolyloxy)-L-phenylalanine n-hexylamide dihydrochloride (PASI-535) was found. We characterized PASI-535 and analyzed the actions of PL, comparing with those of PASI-535 and tranexamic acid (t-AMCHA). (1) PASI-535 strongly inhibited not only fibrinolysis (IC50: 2.9 x 10(-6) M) but also amidolysis (Ki value: 2.9 x 10(-6) M) and fibrinogenolysis (IC50: 4.5 x 10(-6) M) induced by PL. While t-AMCHA which strongly inhibited fibrinolysis (IC50: 6.0 x 10(-5) M), rarely inhibited amidolysis (Ki value: 4.0 x 10(-2) M) and fibrinogenolysis (IC50: 1.0 x 10(-2) M). (2) PL is able to liberate kinins by degrading kininogen. This kinin-generation by PL was inhibited by 2 x 10(-5) M PASI-535. However, it was little inhibited even by 1 x 10(-3) M t-AMCHA. (3) The inhibitory effect of PASI-535 and t-AMCHA on tumor growth was studied. In sarcoma-180 bearing mice, ascites retention and the increase of tumor cells were markedly suppressed by subcutaneous injection of PASI-535, either 30 mg/kg/day or 50 mg/kg/day, for 5 days, and the inhibitory effect was dose-dependent. Although t-AMCHA also reduced both ascites retention and the increase of tumor cells, it needed approximately 40 times (2 g/kg/day) the amount of PASI-535 to exert these effects. PASI-535 may be a useful tool in analyzing the multiplicity of PL actions. Moreover, PASI-535 can be used as an antifibrinolytic drug which has a mechanism of function different from that of t-AMCHA.
authors.affiliation: Kobe Research Projects on Thrombosis and Haemostasis, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Wanaka
authors.forename: S
authors.initials: S
authors.lastname: Okamoto
authors.forename: N
authors.initials: N
authors.lastname: Horie
authors.forename: A
authors.initials: A
authors.lastname: Hijikata-Okunomiya
authors.forename: U
authors.initials: U
authors.lastname: Okamoto
authors.forename: T
authors.initials: T
authors.lastname: Naito
authors.forename: N
authors.initials: N
authors.lastname: Ohno
authors.forename: M
authors.initials: M
authors.lastname: Bohgaki
authors.forename: Y
authors.initials: Y
authors.lastname: Tsuda
authors.forename: Y
authors.initials: Y
authors.lastname: Okada
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005341:Fibrinolysin / Q000037:antagonists & inhibitors*; D005342:Fibrinolysis / Q000187:drug effects; D007700:Kinetics; D007705:Kinins / Q000378:metabolism; D051379:Mice; D008969:Molecular Sequence Data; D010455:Peptides / Q000737:chemistry; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D012513:Sarcoma, Experimental / Q000188:drug therapy*; D013379:Substrate Specificity
chemical_list: D004791:Enzyme Inhibitors; D007705:Kinins; C101005:PASI 535; D010455:Peptides; D010649:Phenylalanine; D005341:Fibrinolysin